Michael B Rothberg1, Marya D Zilberberg2, Penelope S Pekow3, Aruna Priya3, Sarah Haessler4, Raquel Belforti5, Daniel Skiest4, Tara Lagu3, Thomas L Higgins6, Peter K Lindenauer3. 1. Center for Value-Based Care Research, Medicine Institute, Cleveland Clinic, Cleveland, OH, USA rothbem@ccf.org. 2. EviMed Research Group, LLC, Goshen, MA, USA. 3. Center for Quality of Care Research, Baystate Medical Center, Springfield, MA, USA. 4. Division of Infectious Diseases, Baystate Medical Center, Springfield, MA, USA. 5. Division of General Medicine, Baystate Medical Center, Springfield, MA, USA. 6. Division of Pulmonary/Critical Care Medicine, Baystate Medical Center, Springfield, MA, USA.
Abstract
OBJECTIVES: Guidelines for treatment of healthcare-associated pneumonia (HCAP) recommend empirical therapy with broad-spectrum antimicrobials. Our objective was to examine the association between guideline-based therapy (GBT) and outcomes for patients with HCAP. PATIENTS AND METHODS: We conducted a pharmacoepidemiological cohort study at 346 US hospitals. We included adults hospitalized between July 2007 and June 2010 for HCAP, defined as patients admitted from a nursing home, with end-stage renal disease or immunosuppression, or discharged from a hospital in the previous 90 days. Outcome measures included in-hospital mortality, length of stay and costs. RESULTS: Of 85 097 patients at 346 hospitals, 31 949 (37.5%) received GBT (one agent against MRSA and at least one against Pseudomonas). Compared with patients who received non-GBT, those who received GBT had a heavier burden of chronic disease and more severe pneumonia. GBT was associated with higher mortality (17.1% versus 7.7%, P < 0.001). Adjustment for demographics, comorbidities, propensity for treatment with GBT and initial severity of disease decreased, but did not eliminate, the association (OR 1.39, 95% CI 1.32-1.47). Using an adaptation of an instrumental variable analysis, GBT was not associated with higher mortality (OR 0.93, 95% CI 0.75-1.16). Adjusted length of stay and costs were also higher with GBT. CONCLUSIONS: Among patients who met HCAP criteria, GBT was not associated with lower adjusted mortality, length of stay or costs in any analyses. Better criteria are needed to identify patients at risk for MDR infections who might benefit from broad-spectrum antimicrobial coverage.
OBJECTIVES: Guidelines for treatment of healthcare-associated pneumonia (HCAP) recommend empirical therapy with broad-spectrum antimicrobials. Our objective was to examine the association between guideline-based therapy (GBT) and outcomes for patients with HCAP. PATIENTS AND METHODS: We conducted a pharmacoepidemiological cohort study at 346 US hospitals. We included adults hospitalized between July 2007 and June 2010 for HCAP, defined as patients admitted from a nursing home, with end-stage renal disease or immunosuppression, or discharged from a hospital in the previous 90 days. Outcome measures included in-hospital mortality, length of stay and costs. RESULTS: Of 85 097 patients at 346 hospitals, 31 949 (37.5%) received GBT (one agent against MRSA and at least one against Pseudomonas). Compared with patients who received non-GBT, those who received GBT had a heavier burden of chronic disease and more severe pneumonia. GBT was associated with higher mortality (17.1% versus 7.7%, P < 0.001). Adjustment for demographics, comorbidities, propensity for treatment with GBT and initial severity of disease decreased, but did not eliminate, the association (OR 1.39, 95% CI 1.32-1.47). Using an adaptation of an instrumental variable analysis, GBT was not associated with higher mortality (OR 0.93, 95% CI 0.75-1.16). Adjusted length of stay and costs were also higher with GBT. CONCLUSIONS: Among patients who met HCAP criteria, GBT was not associated with lower adjusted mortality, length of stay or costs in any analyses. Better criteria are needed to identify patients at risk for MDR infections who might benefit from broad-spectrum antimicrobial coverage.
Authors: Marco Falcone; Salvatore Corrao; Giuseppe Licata; Pietro Serra; Mario Venditti Journal: Intern Emerg Med Date: 2012-06-12 Impact factor: 3.397
Authors: R T Attridge; C R Frei; M I Restrepo; K A Lawson; L Ryan; M J V Pugh; A Anzueto; E M Mortensen Journal: Eur Respir J Date: 2011-03-24 Impact factor: 16.671
Authors: Stephan Harbarth; Jorge Garbino; Jérome Pugin; Jacques A Romand; Daniel Lew; Didier Pittet Journal: Am J Med Date: 2003-11 Impact factor: 4.965
Authors: Brandon J Webb; Benjamin S Dangerfield; Jabraan S Pasha; Neera Agrwal; Holenarasipur R Vikram Journal: Respir Med Date: 2012-08-21 Impact factor: 3.415
Authors: Brandon J Webb; Eddie Stenehjem; Kristin Dascomb; Mark Metersky; Holenarasipur R Vikram; Nathan C Dean Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191
Authors: Russell T Attridge; Christopher R Frei; Mary Jo V Pugh; Kenneth A Lawson; Laurajo Ryan; Antonio Anzueto; Mark L Metersky; Marcos I Restrepo; Eric M Mortensen Journal: J Crit Care Date: 2016-08-11 Impact factor: 3.425
Authors: Sarah Haessler; Tara Lagu; Peter K Lindenauer; Daniel J Skiest; Aruna Priya; Penelope S Pekow; Marya D Zilberberg; Thomas L Higgins; Michael B Rothberg Journal: J Hosp Med Date: 2017-11 Impact factor: 2.960
Authors: Barbara E Jones; Makoto M Jones; Benedikt Huttner; Gregory Stoddard; Kevin Antoine Brown; Vanessa W Stevens; Tom Greene; Brian Sauer; Karl Madaras-Kelly; Michael Rubin; Matthew Bidwell Goetz; Matthew Samore Journal: Clin Infect Dis Date: 2015-07-29 Impact factor: 9.079
Authors: Thomas P Lodise; Weihong Fan; David C Griffith; Michael N Dudley; Katherine A Sulham Journal: Antimicrob Agents Chemother Date: 2017-12-21 Impact factor: 5.191
Authors: Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Weihong Fan; Andrew F Shorr Journal: Antimicrob Resist Infect Control Date: 2017-12-06 Impact factor: 4.887
Authors: Joshua P Metlay; Grant W Waterer; Ann C Long; Antonio Anzueto; Jan Brozek; Kristina Crothers; Laura A Cooley; Nathan C Dean; Michael J Fine; Scott A Flanders; Marie R Griffin; Mark L Metersky; Daniel M Musher; Marcos I Restrepo; Cynthia G Whitney Journal: Am J Respir Crit Care Med Date: 2019-10-01 Impact factor: 21.405